Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
75.5M
-
Shares change
-
-134K
-
Total reported value, excl. options
-
$89.1M
-
Value change
-
-$399K
-
Put/Call ratio
-
0
-
Number of buys
-
30
-
Number of sells
-
-32
-
Price
-
$1.18
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q3 2023
114 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q3 2023.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.5M shares
of 229M outstanding shares and own 32.99% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34.9M shares), BlackRock Inc. (9.29M shares), VANGUARD GROUP INC (8.31M shares), Defender Capital, LLC. (5.18M shares), GEODE CAPITAL MANAGEMENT, LLC (2.77M shares), STATE STREET CORP (2.02M shares), Prescott General Partners LLC (1.85M shares), RAFFLES ASSOCIATES LP (1.59M shares), NORTHERN TRUST CORP (1.2M shares), and Laurion Capital Management LP (1.14M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.